Loren Data's SAM Daily™

FBO DAILY ISSUE OF SEPTEMBER 10, 2006 FBO #1749
SOLICITATION NOTICE

B -- Mutational Spectrum Analysis of Fumarate Hydratase and Birt-Hogg-Dube and MET Genes

Notice Date

9/8/2006
 

Notice Type

Solicitation Notice
 

NAICS

541380 — Testing Laboratories
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 

ZIP Code

20852
 

Solicitation Number

NCI-60205-NG
 

Response Due

9/22/2006
 

Archive Date

10/7/2006
 

Description

In accordance with Simplified Acquisition procedures, the National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Genetic Epidemiologic Branch (GEB), plans to procure, on a sole source basis, for Mutational Spectrum Analysis of Fumarate Hydratase and Birt-Hogg-Dube and MET Genes in non-clear cell Kidney Cancer in hospital based case-control studies from Transgenomic, Inc., 12325 Emmet Street, Omaha, NE 68164. The North American Industry Classification System Code is 541380 and the business size standard is $11M. The GEB is conducting a case-control study of kidney cancer. The purpose of the study is to investigate a number of environmental, occupational, and personal risk factors for kidney cancer. NCI has collected formalin fixed paraffin embedded tumor material from 200 non-clear cell renal tumors. Paraffin-embedded tissue blocks and frozen tissue were also obtained, and frozen tumor material from 80% of cases with paraffin blocks. Pathology tissue from cancer patients provides increasing opportunities for the study of biological questions relevant to tumor etiology and for detecting early markers of disease. Pathology specimens provide a resource for examining DNA to screen for mutation in renal cancer susceptibility genes including Birt-Hogg-Dube (BHD), MET and fumarate hydratase (FH), and can be used to compare tumors that are associated with different risk factors, thus strengthening associations that might be made between exposures and disease. To accomplish this, DNA tumor samples will be screened for FH and MET gene mutations and evaluation of the role of mutations in the BHD in the etiology of chromophobe and oncocytoma RCC by screening for the BHD gene mutation. Transgenomic, Inc. will receive 10 samples each month, slides and tumor DNA, to design amplicons for each target fragment for analysis of exons of BHD, FH, and MET genes. Transgenomic, Inc. is the only contractor known to the NCI that is uniquely qualified to carry out this effort because they have developed a unique technological approach using a combination of Surveyor Nuclease, DHPLC, and direct DNA sequencing for mutation detection. The quality control and their technological approach are best for the mutation detection of the samples. The sensitivity and specificity of the technology used by Transgenomic will provide results that are more informative This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above services, and has the support of the above listed partners, it may submit a statement of capabilities. The statement of capabilities and any other information must be in writing and must contain sufficient detail to allow NCI to determine if the party can perform the requirement. An original and one copy of the capability statements must be received in the contracting office by September 22, 2006 at 1 PM. All questions must be in writing and can be faxed to (301) 402-4513 or sent via electronic mail to Malinda Holdcraft at holdcram@exchange.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered in and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-60205-NG.
 

Place of Performance

Address: Nebraska

Zip Code: 68164

Country: UNITED STATES
 

Record

SN01137484-W 20060910/060908220422 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |